TY - JOUR
T1 - Vancouver Declaration on Global Headache Patient Advocacy 2018
AU - Dodick, David
AU - Edvinsson, Lars
AU - Makino, Tomohiko
AU - Grisold, Wolfgang
AU - Sakai, Fumihiko
AU - Jensen, Rigmor
AU - Balch, Alan
AU - Ruiz de la Torre, Elena
AU - Henscheid-Lorenz, Deborah
AU - Craven, Audrey
AU - Ashina, Messoud
N1 - Funding Information:
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DWD has provided consultation, within the past 5 years, to Acorda, Allergan, Amgen, Alder, Promius, eNeura, Eli Lilly & Company, Insys Therapeutics, Autonomic Technologies, Teva, Xenon, Tonix, Trigemina, Boston Scientific, Nocira, Zosano, Biocentric, Biohaven, Magellan, Theranica, Charleston Laboratories, Supernus, Gore and Electrocore. Royalties: Oxford University Press and Cambridge University Press (book royalty); he receives editorial/honoraria from UpToDate, MedNet LLC, Peer View Institute for Medical Education, Medicom, Chameleon Communications, Medscape, WebMD, Academy for Continued Healthcare Learning, Haymarket Medical Education, Global Scientific Communications, HealthLogix, Miller Medical, Academy for Continued Healthcare Learning, MeetingLogiX, Wiley Blackwell, Medicom; stock/options: Nocira, Epien, Healint, Theranica, and Mobile Health; he has a consulting use agreement with NAS and Myndshft; he has a board position at King-Devick Technologies, Inc. and Epien Inc. LE has given lectures and received unrestricted grants from AMGEN/ Novartis and TEVA. RJ has given lectures and conducted trials for ATI, Merck, and Allergan, is a Director in LTB and Trustee in IHS. MA discloses he is a consultant, speaker or scientific advisor for Allergan, Amgen, Alder, ATI, Eli Lilly, Novartis, and Teva, primary investigator for Amgen 20120178 (Phase 2), 20120295 (Phase 2), 20130255 (OLE), 20120297 (Phase 3), Alder ALD403-CLIN-001 (Phase 3), Amgen PAC1 20150308 (Phase 2a), and GM-11 gamma-Core-R trials. The other authors have no conflicting interests.
Publisher Copyright:
© International Headache Society 2018.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Background: Headache disorders comprise the three most prevalent medical disorders globally and contribute almost 20% to the total burden of neurologic illness. Although the experience of a recurrent headache disorder tends to be highly individualized, patient preferences tend to be a low priority in guidelines for the management of patients with headache. Methods: In September 2017, the first Global Patient Advocacy Summit was convened, bringing together patients, patient advocates, patient advocacy organizations, healthcare professionals, pharmaceutical manufacturers, scientists, and regulatory agencies to advance issues of importance to patients affected by headache worldwide. Results: Presentations and discussion covered multiple issues, such as improving access to appropriate medical care; incorporating the insights of independent patient advocates and advocacy organizations; leveraging the insights, experience and influence of leading health and neurological organizations; and raising awareness of the role of regulatory agencies in disease advocacy. Attendees agreed that it is important to understand and promote the global, regional, and local interests of people with headache disorders, as well as challenge the pervasive stigma associated with headache. They also agreed that those with severe, recurrent, or disabling headache disorders should have reliable access to competent medical care; healthcare professionals should have access to adequate training in Headache Medicine; global benchmarks should be established for accurate diagnosis and the use of evidence-based treatments in patients with headache; and that information is needed about consultation, diagnosis, and treatment of headache, particularly in regard to patient preferences. Conclusion: Based on the group’s consensus around these issues, a series of statements was developed, and they are collectively presented herein as the Vancouver Declaration on Global Headache Patient Advocacy 2018.
AB - Background: Headache disorders comprise the three most prevalent medical disorders globally and contribute almost 20% to the total burden of neurologic illness. Although the experience of a recurrent headache disorder tends to be highly individualized, patient preferences tend to be a low priority in guidelines for the management of patients with headache. Methods: In September 2017, the first Global Patient Advocacy Summit was convened, bringing together patients, patient advocates, patient advocacy organizations, healthcare professionals, pharmaceutical manufacturers, scientists, and regulatory agencies to advance issues of importance to patients affected by headache worldwide. Results: Presentations and discussion covered multiple issues, such as improving access to appropriate medical care; incorporating the insights of independent patient advocates and advocacy organizations; leveraging the insights, experience and influence of leading health and neurological organizations; and raising awareness of the role of regulatory agencies in disease advocacy. Attendees agreed that it is important to understand and promote the global, regional, and local interests of people with headache disorders, as well as challenge the pervasive stigma associated with headache. They also agreed that those with severe, recurrent, or disabling headache disorders should have reliable access to competent medical care; healthcare professionals should have access to adequate training in Headache Medicine; global benchmarks should be established for accurate diagnosis and the use of evidence-based treatments in patients with headache; and that information is needed about consultation, diagnosis, and treatment of headache, particularly in regard to patient preferences. Conclusion: Based on the group’s consensus around these issues, a series of statements was developed, and they are collectively presented herein as the Vancouver Declaration on Global Headache Patient Advocacy 2018.
KW - Headache patient advocacy
KW - global headache
KW - headache disorders
UR - http://www.scopus.com/inward/record.url?scp=85048267909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048267909&partnerID=8YFLogxK
U2 - 10.1177/0333102418781644
DO - 10.1177/0333102418781644
M3 - Article
C2 - 29882695
AN - SCOPUS:85048267909
SN - 0333-1024
VL - 38
SP - 1899
EP - 1909
JO - Cephalalgia
JF - Cephalalgia
IS - 13
ER -